美股异动丨礼来涨超3%创新高，公布实验性减肥药物2期临床研究的积极结果

Core Viewpoint - Eli Lilly (LLY.US) shares rose over 3%, reaching a record high of $1019.98, following positive results from the Phase 2 clinical trial of the experimental weight loss drug eloralintide [1] Group 1: Clinical Trial Results - The Phase 2 clinical trial of eloralintide showed that all dosage groups achieved the primary endpoint at week 48, with an average weight reduction ranging from 9.5% to 20.1% [1] - The average weight reduction in the placebo group was only 0.4%, indicating a significant efficacy of eloralintide compared to the placebo [1] Group 2: Future Developments - Based on the positive trial results, the company plans to initiate enrollment for the Phase 3 clinical trial of eloralintide for obesity treatment next month [1]